| 1 |
34420059 | Prognostic value of natural killer cell activity for patients with HER2 + advanced gastric cancer treated with first-line fluoropyrimidine-platinum doublet plus trastuzumab. | 2022 Apr |
2 |
| 2 |
32970266 | External validity of docetaxel triplet trials in advanced gastric cancer: are there patients who still benefit? | 2021 Mar |
1 |
| 3 |
31251346 | Quality of Life During Palliative Systemic Therapy for Esophagogastric Cancer: Systematic Review and Meta-Analysis. | 2020 Jan 1 |
1 |
| 4 |
31851321 | HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial. | 2020 Sep 1 |
1 |
| 5 |
33042632 | Trastuzumab plus docetaxel and capecitabine as a first-line treatment for HER2-positive advanced gastric or gastroesophageal junction cancer: a phase II, multicenter, open-label, single-arm study. | 2020 |
2 |
| 6 |
30088161 | Phase II study of trastuzumab with modified docetaxel, cisplatin, and 5 fluorouracil in metastatic HER2-positive gastric cancer. | 2019 Mar |
1 |
| 7 |
28936560 | Multicenter phase II study of trastuzumab plus S-1 alone in elderly patients with HER2-positive advanced gastric cancer (JACCRO GC-06). | 2018 May |
2 |
| 8 |
29090377 | Trastuzumab in Combination with FOLFIRI in Patients with Advanced HER2-Positive Gastro-Esophageal Adenocarcinoma: A Retrospective Multicenter AGEO Study. | 2018 Feb |
1 |
| 9 |
27599830 | Prognostic significance of performing universal HER2 testing in cases of advanced gastric cancer. | 2017 May |
1 |
| 10 |
26254345 | Second-line Treatment of Advanced Gastric Cancer: Current Options and Future Perspectives. | 2015 Sep |
1 |
| 11 |
26359224 | Advancing pharmacological treatment options for advanced gastric cancer. | 2015 |
2 |
| 12 |
24749947 | Innovative personalized medicine in gastric cancer: time to move forward. | 2014 Jul |
1 |
| 13 |
23680713 | Esophageal carcinoma: are modern targeted therapies shaking the rock? | 2013 Jul |
1 |
| 14 |
24057416 | Trastuzumab: a review of its use in HER2-positive advanced gastric cancer. | 2013 Sep |
1 |
| 15 |
23007148 | Combination of trastuzumab and triple FLOT chemotherapy (5-fluorouracil/leucovorin, oxaliplatin, and docetaxel) in patients with HER2-positive metastatic gastric cancer: report of 3 cases. | 2012 |
1 |
| 16 |
23197882 | Advanced gastric cancer: is there enough evidence to call second-line therapy standard? | 2012 Nov 28 |
1 |
| 17 |
21673877 | HER2 Testing in Gastric/Gastroesophageal Junction Adenocarcinomas: Unique Features of a Familiar Test. | 2011 Mar |
1 |
| 18 |
21129604 | Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target. | 2010 Nov |
1 |
| 19 |
17611667 | Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer. | 2007 Aug |
1 |
| 20 |
12680178 | Implication of HER-2/neu overexpression for the efficacy of oral fluoropyrimidine-based adjuvant chemotherapy in the patients with estrogen receptor negative breast cancer after surgery. | 2003 Jan-Feb |
2 |